+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nintedanib"

From
From
Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
From
From
Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets - Product Thumbnail Image

Idiopathic Pulmonary Fibrosis Disease Treatment: Global Markets

  • Report
  • October 2020
  • 60 Pages
  • Global
From
Global Respiratory Drugs Market Outlook 2027 - Product Thumbnail Image

Global Respiratory Drugs Market Outlook 2027

  • Report
  • May 2020
  • 185 Pages
  • Global
From
From
From
From
Ofev (Nintedanib) - Drug Insight and Market Forecast - 2030 - Product Thumbnail Image

Ofev (Nintedanib) - Drug Insight and Market Forecast - 2030

  • Report
  • August 2020
  • 80 Pages
  • Global
From
From
From
Loading Indicator

Nintedanib is a drug used to treat respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a tyrosine kinase inhibitor that works by blocking the activity of certain proteins that are involved in the development of fibrosis. Nintedanib is approved by the US Food and Drug Administration (FDA) for the treatment of IPF and SSc-ILD. It is also approved in Europe and other countries for the treatment of IPF. Nintedanib is marketed by Boehringer Ingelheim, a German pharmaceutical company. Other companies involved in the market include Novartis, AstraZeneca, and GlaxoSmithKline. Show Less Read more